Table 1.
Demographic and clinical characteristics.
| Variables | TD (n = 32) | Non-TD (n = 31) | HC (n = 32) | F/T/X 2 | P |
|---|---|---|---|---|---|
| Sex (M/F) | 20/12 | 19/12 | 19/13 | 4, 697 | 0.096 |
| Age (years) | 46.9 ± 10 | 45.7 ± 7.5 | 45.6 ± 7.7 | 0.174 | 0.841 |
| Education(years) | 11.5 ± 2.4 | 12.4 ± 2.2 | 11.9 ± 2.2 | 1.268 | 0.286 |
| Duration of illness(years) | 22.8 ± 10.2 | 22.6 ± 8.4 | — | 0.071 | 0.943 |
| PANSS | |||||
| Positive subscore | 14.4 ± 5.5 | 13.8 ± 5.6 | — | 0.405 | 0.687 |
| Negative subscore | 22.3 ± 5.8 | 17.3/6.2 | — | 3.311 | 0.002 |
| General psychopathological subscore | 30.9 ± 5.6 | 31.2 ± 7.2 | — | −0.157 | 0.876 |
| Total score | 67.6 ± 11.7 | 62.3 ± 13.8 | — | 1.657 | 0.103 |
| AIMS | 8.6 ± 4.2 | — | — | — | |
| CPZ equivalents (mg) | 508 ± 266 | 530 ± 224 | — | −0.35 | 0.727 |
| Haloperidol | 1 | 0 | |||
| Amisulpride | 1 | 0 | |||
| Clozapine | 16 | 10 | |||
| Risperidone | 4 | 6 | |||
| Olanzapine | 8 | 8 | |||
| Quetiapine | 2 | 0 | |||
| Perphenazine | 0 | 2 | |||
| Pipotiazine | 0 | 1 | |||
| Sulpiride | 0 | 1 | |||
| Aripiprazole | 0 | 2 | |||
| Lurasidone | 0 | 1 | |||
p-value indicate significant differences (p < 0.05) in appropriate statistical tests. PANSS: positive and negative syndrome scale; AIMS: Abnormal Involuntary Movement Scale; CPZ: chlorpromazine; TD: patients with schizophrenia and tardive dyskinesia; non-TD: patients with schizophrenia and without tardive dyskinesia; HC healthy subjects.